

July 16, 2024

Company name	CellSource Co., Ltd.
Name of representative	Takashi Sawada, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information for inquiries	Katsuji Onishi, Executive Officer and General Manager of Administration Tel: +81-3-6455-5308

## CellSource Awarded Contract to Operate Online Information Sessions for Tokyo Metropolitan Government's Egg Freezing Program

CellSource Co., Ltd. (Representative Director & CEO: Takashi Sawada, hereinafter "CellSource"), a regenerative medicine related business, announces that it has been awarded a contract by the Tokyo Metropolitan Government to operate "Online Information Sessions for Egg Freezing Candidates."

### ■ About the contracted services

CellSource will be responsible for operating online information sessions for candidates eligible for the Tokyo Metropolitan Government's "Egg Freezing Cost Subsidy" program. Participation in these information sessions, designed to provide accurate knowledge about egg freezing, is a requirement for those seeking the subsidy. This ensures that interested individuals can undergo egg freezing in a safe and secure environment.

CellSource provides the egg freezing storage service "Egg Freezing Anshin Bank." CellSource will execute this contracted service by leveraging its experience in conducting numerous information sessions on egg freezing and storage for individuals considering the procedure and companies introducing related programs as part of their employee benefits.

### ■ About Egg Freezing Anshin Bank\*

卵子凍結

あんしん  
バンク

This is a specialized service for the storage of frozen eggs. We are entrusted with the storage of eggs collected and frozen at our partner medical institutions.

We store frozen eggs safely for a long period of time in our well-controlled facilities and dedicated transportation services.

Official Site: <https://ranshi-touketsu.jp/> (in Japanese)

\* Egg Freezing Anshin Bank is a trademark of CellSource Co., Ltd.

### **About CellSource Co., Ltd.**

We specialize in advancing the industrialization of regenerative medicine, providing services such as processing adipose-derived stem cells, synovial-derived stem cells, and blood, as well as offering regulatory compliance support to medical institutions engaged in regenerative medicine. Operating under a Specific Cell Processing Manufacturing License (Facility Number: FA3160006) in accordance with the Act on the Safety of Regenerative Medicine, we have handled over 93,000 cell-related procedures. With a wealth of experience, we strive to offer reliable services to medical institutions and contribute to research and technological development.

Representative Director and CEO: Takashi Sawada

Representative Director and CXO: Masato Tsumamoto

Location: Shibuya Cast 11F, 1-23-21 Shibuya, Shibuya-ku, Tokyo

Website: <https://www.cellsource.co.jp/en/>

*Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete. In the event of any translation error or misunderstanding, the original Japanese version shall prevail.*